About Our Lab
The Burridge lab works in the field of pharmacogenomics (precision medicine), cardio-oncology, cardiovascular disease modeling, cultivated meat, regenerative medicine, and cancer, using induced pluripotent stem cells (iPSCs) as our model. We specialize in large-scale hiPSC projects that required reprogramming, sequencing, editing, differentiating, and phenotyping hundreds of hiPSC lines.
We are responsible for a number of firsts including: the first directed cardiac differentiation protocol (Burridge et al., 2006), the first non-integrating reprogramming of blood to iPSC (Burridge et al., 2011), the first chemically defined differentiation protocol (Burridge et al., 2014), the first demonstration that doxorubicin-induced cardiotoxicity is a genomic disease (Burridge et al., 2016) and most recently, the first cost-effective method of culturing iPSC (Kuo et al., 2020).
Ongoing projects include;
- Studying the role of the genome in complex disease traits, understanding how single genetic variants modulate drug efficacy and toxicity, predicting which patients will experience successful therapy or suffer adverse drug responses, and discovering new drugs to overcome these complications.
- Developing new tools to reprogram, culture, and differentiate iPSC in an efficient and cost-effective manner to improve the use, scale, and ubiquity of these across all areas of research.
- The applications of iPSC-derived cells for cultivated meat.
- Studying the genomics of arrhythmia and sudden cardiac death and devising precision medicine-led drug discovery.
- The applications of iPSC and direct reprogramming in regenerative medicine, repairing the heart after a heart attack or ameliorating the effects of heart failure.
- How heritable (germline) variation influences cancer progression, oncology drug efficacy, and acquisition of resistance.